E. G. Hahn

E. G. Hahn

Auto-generated profile, based on publicly available information

E. G. Hahn

Universität Erlangen

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2006 in Endoscopy
Verified
Journal Article
Open access
PDF file
JMJ. Maiss
J. Maiss
CDC. Dumser
C. Dumser
YZY. Zopf
Y. Zopf
ANA. Naegel
A. Naegel
NKN. Krauss
N. Krauss
DSD. Schwab
D. Schwab
Background and Study Aims: Hemoclip therapy is a well-established procedure in the treatment of gastrointestinal bleeding. Although new products are provided periodically by the industry, comparative investigations are lacking. We compared two different hemoclip devices in an experimental setting, assessing them using objective hemostatic parameters. Materials and Methods: We compared two disposable clip devices (Olympus HX-200L-135 (n = 40) vs. Wilson-Cook Tri-Clip (n = 40)) in an experimental setting using the compact Erlangen Active Simulator for Interventional Endoscopy (compactEASIE) training model equipped with an upper gastrointestinal-organ package for bleeding simulation. This was a randomized, prospective, controlled trial. Four investigators with different levels of endoscopic experience applied ten hemoclip devices of each type to the spurting vessels, the clips allocated using a randomized list for each investigator. The efficacy of hemostasis was determined by continuous measurement of the pressure within the afferent vessel before and after clip application and calculation of the relative reduction of vessel diameter by the clip device. The system pressure was recorded over the period from 1 minute before to 1 minute after clip application. A secondary end point was a subjective assessment of the whole clip application procedure by the endoscopist and the assisting nurse, using a visual analog scale (0 - 100, with 100 representing the best experience). Results: A total of 39/40 clips of each type were applied successfully. Both clip devices led to a significant increase in system pressure, representing significant relative reduction of vessel diameter (Olympus 5.4 ± 7.5 %, p < 0.001; Cook 4.9 ± 8.0 %, p < 0.001). Overall, there was no significant difference between the two devices (P = 0.756). However, the investigator with the least experience in endoscopy (< 100 procedures) produced significantly inferior results compared with the other three investigators, who had performed between 2000 and 6000 procedures each (P < 0.05). We found no evidence of a learning curve from the intra-observer results. The devices received good, but not significantly different, overall ratings by the endoscopists (Olympus 69 ± 24 vs. Wilson-Cook 65 ± 16) and by the assisting nurses (Olympus 77 ± 9 vs. Wilson-Cook 70 ± 22). Conclusions: Using an established cadaveric training model, no significant difference was found between the two types of hemoclip devices with respect to their “hemostatic efficacy”. However, the experience of the endoscopist appears to play a major role in successful clip application. The use of a feedback mechanism in emergency endoscopy training, using continuous intravessel pressure monitoring, may substantially enhance the efficacy of training, resulting in a similar improvement in clinical results.

26 August 2002 in Endoscopy
Verified
Journal Article
Closed access
JHJuergen Hochberger
Juergen Hochberger
JMJ. Maiss
J. Maiss
EHE. G. Hahn
E. G. Hahn
Quality management and optimal patient care are two of the most important issues in clinical medicine today. While evidence-based medicine is rapidly becoming the “gold standard” for treatment modalities, the responsibility for education, including theoretical background as well as acquisition and refinement of manual skills in gastrointestinal endoscopy, remains in the hands of the individual physician. New endoscopy simulators have rekindled the discussion as to whether it is preferable for training in basic manual skills to take place away from the patient [ 1 ]. The paper of Ferlitsch et al. from Vienna, published in this issue of Endoscopy, shows that the use of a simulator could or should form part of future education in diagnostic gastroscopy and colonoscopy. Included in the study were 13 beginners and 11 experts. After a short introductory session on the simulator, all participants were evaluated in a baseline assessment. This included the diagnostic steps of a virtual gastroscopy and colonoscopy procedure, and two modules concerned with endoscopic dexterity and skills, called “Endobasket” and “Endobubble.” The beginners were then divided into two groups, with seven participants in an intensive training group and six in a control group. This was followed by a 3-week training program of 2 hours of simulator practice daily for 5 days a week, which was offered only to the intensive training group. After 3 weeks the intensively trained group performed significantly better using the simulator than the untrained group, and reduced the initial difference from the expert group to a nonsignificant level. The authors took a simple but important step in the validation of the Symbionix computer simulator as a teaching tool [ 2 ] [ 3 ]. Experts did better than beginners in the gastroscopy and colonoscopy procedures, as well as in the two virtual skills test modules. The higher performance level of the experts demonstrated the simulator’s ability to identify specific quality aspects of the endoscopic procedure. Prior experience in computer games, age, and sex did not have any influence on the result. The study is published in parallel with one described in the June 2002 issue of Surgical Endoscopy [ 4 ]. This was carried out using a second type of endoscopy simulator, the “PreOp” of the Immersion Medical Corporation, USA. The authors, from London, also studied the correlation between clinical endoscopic competence in the beginners’ state and judgement given by the computer simulator. The participants had to perform a virtual flexible sigmoidoscopy procedure using the simulator. The percentage of colonic mucosa visualized, the time taken, and the path length of endoscope travel were measured. The 45 participants were divided into three groups: novice (no lower gastrointestinal endoscopy ever performed); intermediate (5 - 50 clinical examinations performed); and trained (more than 200 examinations). There was a significant difference between all three groups with respect to percentage of mucosa visualized and efficiency ratio (% mucosa/time). The novice group was slower and had a longer path length of instrument travel compared with the others. The authors concluded that the “PreOp” virtual reality simulator is a valid discriminator of flexible sigmoidoscopy experience. Unfortunately the study by Ferlitsch et al. lacks a clinical stage, with surveillance of untrained and simulator-trained participants during their first experiences with real patients; this should follow in a subsequent trial soon. As in previous studies [ 3 ], the authors mention some limitations of the simulator. The most difficult part of a gastroscopy procedure is for an endoscopic novice the intubation of the esophagus via mouth, pharynx/hypopharynx, and upper esophageal sphincter. This is not adequately simulated with the tube-like passage in the computer simulator. Concerning the risk of complications, however, intubation of the esophagus is the rather risky and unpleasant part for the patient. Furthermore, the passage of the pylorus and retroflexion are not ideally simulated, and neither are loop formations in the colon, pronounced kinks, or a very mobile sigma as mentioned by the authors. The effect on real endoscopy, especially in colonoscopy, is uncertain. Over-confidence in the computer-trained beginner could potentially result in an increased perforation rate, and therefore increased surveillance may be needed during the adaptation phase. The number of procedures required to attain basic competence in clinical endoscopy seems to be between 100 and 200 procedures for gastroscopy and colonoscopy [ 5 ]. It is hoped that ongoing studies will soon show whether simulator training results in a reduction of this clinical number [ 6 ].

2 December 1998 in Inflammation Research
Verified
Journal Article
Closed access
PDF file
DSD. Schwab
D. Schwab
MRM. Raithel
M. Raithel
EHE. G. Hahn
E. G. Hahn

1 March 2004 in Inflammation Research
Verified
Journal Article
Closed access
PDF file
HSHubert Schwelberger
Hubert Schwelberger
MWM. Weidenhiller
M. Weidenhiller
EHE. G. Hahn
E. G. Hahn
MRM. Raithel
M. Raithel
MKM. A. Kuefner
M. A. Kuefner

4 November 2023 in Clinical and Translational Science
Verified
Journal Article
Open access
EHErik Hahn
Erik Hahn
RCRenae Chavira
Renae Chavira
LWLance Wollenberg
Lance Wollenberg
WTWeiwei Tan
Weiwei Tan
MRMicaela Reddy
Micaela Reddy
Encorafenib is a potent and selective ATP competitive inhibitor of BRAF V600–mutant kinase approved for patients with BRAF‐mutant melanoma and colorectal cancer. Encorafenib is mainly metabolized by cytochrome P450 (CYP) 3A4 in vitro and may be susceptible to drug–drug interactions when co‐administered with CYP3A inhibitors or inducers. The primary objective was to assess the impact of the strong CYP3A inhibitor posaconazole (part 1) and the moderate CYP3A and P‐gp inhibitor diltiazem (part 2) on encorafenib pharmacokinetics in healthy volunteers following a single 50‐mg dose. A total of 32 participants were enrolled (16 each in parts 1 and 2). The area under the curve extrapolated to infinity (AUCinf) and maximum plasma concentration (Cmax) geometric mean for encorafenib increased by 183% and 68.4%, respectively, when co‐administered with posaconazole. Apparent encorafenib clearance decreased from 26.0 to 9.2 L/h when coadministered with posaconazole, and plasma terminal half‐life (t½) of encorafenib increased from 4.3 to 7.3 h. The AUCinf and Cmax geometric mean for encorafenib increased by 83.0% and 44.7%, respectively, when co‐administered with diltiazem. Similarly, the apparent encorafenib clearance decreased from 29.0 to 16.0 L/h when co‐administered with diltiazem, and plasma t½ of encorafenib increased from 6.6 to 7.9 h. There were no deaths, serious adverse events (AEs), or patient discontinuations due to AEs in parts 1 or 2. The most frequently reported treatment‐related AEs were erythema (n = 14; 88%) and headache (n = 11; 69%) in part 1 and headache (n = 7; 44%) in part 2. The results of this study indicate that co‐administration of encorafenib with strong or moderate CYP3A4 inhibitors should be avoided.

18 October 2007 in Pneumologie
Verified
Journal Article
Closed access
SZS. Zirlik
S. Zirlik
SLS. Lampert
S. Lampert
EHE. G. Hahn
E. G. Hahn
GWG. H. Wiest
G. H. Wiest
WBW. M. Brückl
W. M. Brückl
Die Therapie des nicht-kleinzelligen Bronchialkarzinoms (NSCLC) erfolgt derzeit stadienadaptiert aufgrund der Erkenntnisse aus klinischen Studien. Das Wissen über spezielle molekulare Veränderungen im Tumor wird (noch) nicht herangezogen, um eine gezielte individuelle Behandlung zu entscheiden. Durch den Einsatz moderner Hochdurchsatz-Verfahren und Analysemöglichkeiten (z. B. Gen-Chip Analysen) erfolgt derzeit in der Onkologie eine exponentielle Zunahme des Wissens über die genetischen Veränderungen in den Zellen und dem Zusammenspiel der Proteine untereinander. Hier kristallisieren sich in jüngster Zeit immer mehr molekulare Faktoren mit prädiktiver (d. h. Vorhersage des Tumoransprechens) und prognostischer (d. h. Vorhersage des Überlebens) Bedeutung beim NSCLC heraus. Zu ihnen zählen unter anderem ERCC1, RRM1 und bestimmte Rezeptor-Tyrosinkinasen. Erste prospektive Studien zeigen bereits, dass die Auswahl der Therapeutika gezielter vorgenommen werden kann, wenn molekulare Marker zuvor aus dem Tumor bestimmt werden. Dieser Übersichtsartikel soll einen Einblick geben, welchen Stellenwert molekulare Marker für die Therapieentscheidung sowohl in der adjuvanten als auch in der palliativen Situation derzeit haben und was in Zukunft möglicherweise in die klinische Praxis übernommen werden wird. The treatment of patients with non-small cell lung carcinoma (NSCLC) is guided by results from clinical studies. Data about molecular changes in the tumour are not used (up to now) to decide for an individualised, tumour-tailored therapy. High-throughput technologies and modern analytical methods (e. g., microarrays) lead to exponentially increasing knowledge about genetic changes in the cells and the interaction of proteins. This results in the discovery of molecular factors with high predictive (prediction of tumour response) and prognostic (prediction of survival) value in NSCLC. Among these are ERCC1, RRM1 and some receptor tyrosine kinases. Preliminary data of prospective studies have shown promising results for the selection of specific drugs, when these tumour markers were analysed. Therefore, this review focuses on the actual value of molecular markers for decision-making in the adjuvant and palliative setting and their probable future introduction into clinical practice.